Altrenogest (Regu-Mate) - progestin

Altrenogest, most commonly known by the brand name Regu-Mate, is a synthetic progestin widely used in equine reproductive management and behavioral control. As a potent progesterone analog, altrenogest mimics the effects of naturally occurring progesterone in the mare's reproductive system, providing veterinarians and horse owners with a valuable tool for managing estrous cycles, supporting at-risk pregnancies, and controlling estrus-related behavioral issues that interfere with training and performance. Since its FDA approval for veterinary use, altrenogest has become the gold standard for progestin therapy in mares, offering reliable and predictable results when used according to established protocols.

The mechanism of action of altrenogest involves binding to progesterone receptors throughout the mare's reproductive system and central nervous system, effectively suppressing the hormonal cascade that leads to estrus behavior and ovulation. By maintaining elevated progestin levels, the medication prevents the release of gonadotropin-releasing hormone from the hypothalamus and subsequent follicle-stimulating hormone and luteinizing hormone from the pituitary gland. This negative feedback mechanism keeps mares in a progesterone-dominant state similar to diestrus or early pregnancy, preventing the expression of estrus behavior and associated hormonal fluctuations. The effects are reversible, with normal cycling typically resuming within four to seven days after discontinuation.

Altrenogest is available as an oral solution formulated for ease of daily administration to horses. The standard Regu-Mate product comes as an oil-based liquid containing 0.22% altrenogest, designed for top-dressing on feed or direct oral administration. The product includes a specialized dosing syringe calibrated for accurate measurement based on body weight. Daily administration is required to maintain therapeutic effects, as the drug has a relatively short duration of action. The oral route offers practical advantages for long-term treatment programs, though the requirement for daily dosing demands consistent owner or caretaker compliance to achieve desired outcomes.

The safety profile of altrenogest in horses is well-established when the medication is used according to label directions and appropriate veterinary oversight. Mares generally tolerate the medication well, with adverse effects being uncommon at therapeutic doses. However, altrenogest carries significant risks for human handlers, particularly women of childbearing potential, due to its potent hormonal activity and ability to be absorbed through skin contact. Strict handling protocols are essential, and the medication should only be administered by individuals who have been properly educated about safety precautions. Veterinary supervision is important for ensuring appropriate use, monitoring treatment response, and managing any complications that may arise.

The primary FDA-approved indication for altrenogest in horses is the suppression of estrus in mares, allowing control of the estrous cycle for reproductive and behavioral management purposes. Many mares exhibit significant behavioral changes during estrus, including irritability, difficulty concentrating, aggression toward other horses, frequent urination, and resistance to training or handling. For performance mares where these behaviors interfere with competition schedules or training programs, altrenogest provides effective suppression of estrus signs, allowing mares to maintain consistent behavior and performance throughout their competitive season. The medication is particularly valuable for mares competing in disciplines where hormonal behavioral fluctuations could affect safety or competitive outcomes.

Pregnancy maintenance represents another critical indication for altrenogest therapy, though this use may be extra-label in some jurisdictions. Mares with a history of early pregnancy loss, those with documented luteal insufficiency, or mares in which the corpus luteum has been compromised may require progesterone supplementation to maintain pregnancy until the placenta assumes progesterone production around day 100-120 of gestation. Altrenogest provides reliable progestin support during this vulnerable period, helping to prevent pregnancy loss related to inadequate progesterone levels. Mares that have undergone embryo transfer are commonly placed on altrenogest to support the early pregnancy in the recipient mare.

Estrus synchronization protocols in breeding programs frequently incorporate altrenogest as a component of controlled breeding schedules. By administering altrenogest for a set period and then withdrawing the medication, veterinarians can coordinate the timing of estrus in groups of mares for timed breeding or embryo transfer programs. This synchronization capability offers significant practical advantages for breeding farms managing multiple mares, allowing more efficient use of stallion availability and veterinary resources. Combined with other reproductive technologies and medications, altrenogest contributes to comprehensive breeding management programs aimed at optimizing reproductive efficiency.

Behavioral management beyond simple estrus suppression represents an important application of altrenogest in veterinary practice. Some mares exhibit persistent or severe behavioral problems that owners attribute to hormonal influences, including those related to granulosa cell tumors or other ovarian abnormalities. While altrenogest is not a treatment for underlying ovarian pathology, it may provide symptomatic improvement in behavior while diagnostic evaluation and definitive treatment are pursued. Additionally, some practitioners use altrenogest in mares with anestrus or irregular cycles to help establish more predictable cyclicity for breeding purposes.

Selection of altrenogest over alternative treatments typically depends on the specific clinical situation, treatment goals, and practical considerations. For estrus suppression in performance mares, altrenogest offers advantages including ease of daily oral administration, predictable effects, and well-documented safety when handled appropriately. For pregnancy support, altrenogest provides consistent progestin supplementation without the injection site reactions associated with some injectable progesterone products. Cost considerations, the need for daily administration, and significant human safety concerns are factors that may influence treatment selection. Veterinary guidance helps determine whether altrenogest is the most appropriate option for individual mares and circumstances.

Dosing protocols for altrenogest follow established guidelines based on body weight, with the standard therapeutic dose being 0.044 mg per kilogram of body weight administered orally once daily. For the commonly available Regu-Mate formulation at 0.22% concentration, this translates to approximately 1 mL per 50 kg (110 lbs) of body weight per day. The product is supplied with a calibrated dosing syringe marked in milliliters and corresponding weight ranges to facilitate accurate dosing. Veterinary guidance is essential for establishing appropriate treatment protocols, determining treatment duration, and monitoring response to therapy. Individual mares may occasionally require dose adjustments based on clinical response, though staying within recommended ranges is important for safety.

Typical dosing for an average 500 kg (1100 lb) mare is 10 mL of Regu-Mate (22 mg altrenogest) once daily. For smaller mares or ponies, doses should be proportionally reduced based on body weight, while larger mares including warmbloods and draft crosses may require proportionally larger doses. Accurate weight estimation using a weight tape or scale improves dosing precision and treatment efficacy. The medication should be administered at approximately the same time each day to maintain consistent blood levels. Loading doses are not typically required, as therapeutic effects generally become apparent within a few days of starting treatment at standard doses.

Treatment duration varies based on the indication for therapy. For estrus suppression in performance mares, treatment typically continues throughout the competitive season or as long as behavioral control is needed, which may extend for several months. For pregnancy maintenance, treatment usually begins when pregnancy is confirmed and continues until approximately day 100-120 of gestation when placental progesterone production becomes sufficient. For estrus synchronization protocols, treatment duration is typically 10-14 days followed by withdrawal to induce estrus. The veterinarian determines appropriate treatment duration based on specific goals and individual mare factors.

Administration of altrenogest requires careful attention to both efficacy and human safety. The oral solution can be administered directly into the mare's mouth using the provided dosing syringe, or it can be top-dressed onto a small amount of grain. Direct oral administration ensures complete dosing but requires proper technique to avoid medication loss. When top-dressing on feed, the medication should be placed on a small amount of palatable feed that will be consumed quickly and completely, as the oily nature of the product may cause some mares to sort around treated feed. Ensuring the full dose is consumed is essential for maintaining therapeutic levels and treatment efficacy.

Missed doses should be administered as soon as remembered if discovered within a few hours of the scheduled time. If a dose is significantly delayed, give the missed dose when remembered and return to the regular schedule the following day without doubling doses. Consistency in daily administration is important, as missed doses can result in breakthrough estrus behavior or, in pregnancy maintenance situations, potentially compromise pregnancy support. If doses are missed repeatedly, treatment efficacy may be compromised, and veterinary consultation is advisable. Setting daily reminders helps ensure compliance with the treatment schedule.

Treatment completion and discontinuation protocols depend on the reason for therapy. For estrus suppression, discontinuation results in return of normal cycling and estrus behavior, typically within four to seven days. For mares being treated for pregnancy maintenance, discontinuation timing should be carefully coordinated with the veterinarian based on gestational age and assessment of placental function. Abrupt discontinuation in early pregnancy without sufficient placental progesterone production can result in pregnancy loss. For synchronization protocols, the timing of discontinuation is a deliberate component of the treatment plan, with mares expected to show estrus and ovulate at predictable intervals following withdrawal.

General tolerability of altrenogest in horses is excellent, with the medication being well-accepted by most mares when administered according to label directions. The potent progestational activity of altrenogest means that effects on the reproductive system are expected and desired rather than true adverse effects. Most mares show no obvious side effects during treatment beyond the intended suppression of estrus behavior. Long-term safety data supports the use of altrenogest for extended periods when indicated, though ongoing veterinary monitoring is appropriate for any prolonged treatment program. The most significant safety concerns associated with altrenogest relate to human handlers rather than the horses receiving treatment.

Common effects of altrenogest therapy that owners may observe include changes in behavior related to the suppression of hormonal cycling. Mares typically become calmer and more consistent in temperament, which is often the desired outcome of treatment. Some mares may show mild weight gain during prolonged treatment, possibly related to the metabolic effects of progestins. Uterine effects including accumulation of intrauterine fluid have been reported in some mares, particularly with extended treatment duration. While this is usually not clinically significant, it may be relevant for mares intended for breeding. These effects generally resolve following discontinuation of treatment.

Moderate side effects are uncommon but may include gastrointestinal effects such as mild colic or changes in manure consistency. Prolonged treatment in some mares has been associated with changes in hair coat quality or delayed shedding. Some practitioners report that mares on long-term altrenogest may show decreased bone density, though clinical significance of this finding is unclear. Local irritation to the oral mucosa is possible if concentrated product contacts sensitive tissues repeatedly. Contact the veterinarian if a mare shows persistent gastrointestinal signs, significant changes in appetite or condition, or any unexpected behavioral changes during treatment.

Serious adverse effects in horses receiving altrenogest are rare. The most significant concern relates to inadvertent administration to mares that are already pregnant, which could potentially affect fetal development or mask signs of pregnancy complications. Mares with pre-existing uterine abnormalities may experience complications related to prolonged progestin exposure. Anaphylactic reactions are extremely rare but theoretically possible with any medication. Hepatic effects have been reported rarely with other synthetic progestins, though significant liver toxicity from altrenogest in horses is not well-documented. Any signs of systemic illness, jaundice, or severe adverse reactions warrant immediate veterinary attention and discontinuation of treatment.

Rare effects and critical safety information include recognition that the most important safety concerns with altrenogest relate to human exposure rather than effects on horses. Women who are or may become pregnant must not handle altrenogest due to risks of absorption through skin contact and potential effects on human pregnancy. Skin contact can occur during administration or handling of treated horses. Gloves should always be worn, and exposed skin should be washed immediately if contact occurs. The profound human safety implications make proper handling education essential for anyone involved in administering altrenogest or caring for treated horses. Veterinary consultation is recommended to establish safe handling protocols in any facility using this medication.

Known allergy or hypersensitivity to altrenogest or any component of the formulation represents an absolute contraindication to use. While true allergic reactions to synthetic progestins are uncommon, any mare that has shown previous adverse reactions to altrenogest should not receive the medication again. Cross-reactivity between different progestin compounds is possible, so mares with known sensitivity to other progestins should be treated with caution if altrenogest is considered. The oil-based carrier in oral formulations could potentially cause reactions in mares with sensitivities to specific oil components, though this is rare. Alternative approaches to reproductive or behavioral management should be pursued for mares with known contraindications.

Hepatic dysfunction represents a significant consideration for altrenogest use, as synthetic progestins are metabolized by the liver. Mares with documented liver disease or impaired hepatic function may be unable to properly metabolize altrenogest, potentially leading to accumulation and increased risk of adverse effects. While routine liver function screening is not typically required before initiating altrenogest therapy in otherwise healthy mares, those with known hepatic compromise should be treated with caution or alternative approaches considered. Signs of liver disease including jaundice, weight loss, or photosensitization warrant evaluation before beginning progestin therapy.

Specific life stage and reproductive status considerations significantly influence altrenogest use. Administration to pregnant mares beyond the context of intentional pregnancy support is contraindicated, as exogenous progestins could affect pregnancy outcomes or mask signs of complications. Before initiating altrenogest for estrus suppression, pregnancy should be ruled out through appropriate examination. Mares with active uterine infections should not receive altrenogest until infection is resolved, as progestin-induced cervical closure and uterine environment changes could worsen infection. Mares intended for breeding in the near future should have treatment timing carefully planned, as residual effects on the reproductive tract may temporarily affect fertility.

Other conditions affecting altrenogest use include mares with history of uterine abnormalities such as pyometra, which could be exacerbated by progestin effects on the uterus. Mares with granulosa cell tumors or other hormone-producing ovarian tumors may have unpredictable responses to exogenous progestins. Significant human exposure risk means that altrenogest should not be used in situations where safe handling cannot be ensured, including facilities without adequate safety protocols or where pregnant women may be exposed to treated horses or the medication itself. Current medications and health conditions should always be discussed with the prescribing veterinarian to identify potential contraindications specific to individual mares.

Major drug interactions with altrenogest are not extensively documented in equine medicine, but theoretical interactions exist based on the medication's mechanism of action and metabolic pathways. Concurrent administration with other hormonal medications affecting the reproductive axis could produce additive, synergistic, or antagonistic effects depending on the specific combination. Prostaglandin administration, commonly used in equine reproductive management, directly counteracts the effects of progestins by causing luteolysis and can override altrenogest's estrus-suppressing effects. If prostaglandins are administered to a mare receiving altrenogest, the expected response to altrenogest will be disrupted. The timing and sequence of hormonal medications in reproductive protocols should be carefully planned under veterinary supervision.

Moderate interactions requiring consideration include effects of medications that alter hepatic metabolism. Drugs that induce hepatic enzyme activity could potentially increase altrenogest metabolism, reducing its effectiveness. Conversely, medications that inhibit hepatic enzymes might increase altrenogest levels and effects. While specific equine drug interaction studies are limited, awareness of potential metabolic interactions is prudent when mares are receiving multiple medications. Antimicrobial agents, particularly those known to affect hepatic function or that undergo significant hepatic metabolism, should be used with awareness of potential interactions. Inform the veterinarian about all medications a mare is receiving before beginning altrenogest therapy.

Minor interactions and supplement considerations are not extensively characterized for altrenogest. Some herbal supplements affecting hormone balance could theoretically interact with progestin therapy, though documented interactions are lacking. Supplements affecting liver function or those metabolized by the same hepatic pathways might influence altrenogest disposition. Phytoestrogens in certain feedstuffs, while typically present at low levels, could theoretically influence response to progestin therapy. Practical management involves documenting all supplements and feedstuffs when reproductive management issues arise, allowing identification of potential contributing factors.

Competition drug considerations for altrenogest are significant, as the medication is a prohibited substance under most equine competition rules including FEI and USEF regulations. Altrenogest has documented detection times extending well beyond cessation of administration, with detection reported for weeks to months after treatment depending on the testing sensitivity and duration of prior treatment. Mares intended for competition under drug rules must have altrenogest withdrawn well in advance, with specific timing determined by governing body regulations and veterinary guidance. Consult current FEI or USEF prohibited substance lists and work with a veterinarian familiar with competition drug rules when managing performance mares that may have received altrenogest. Documentation of treatment dates and withdrawal periods is essential for competition horses.

Monitoring requirements during altrenogest therapy depend on the indication and treatment duration. For estrus suppression, periodic observation confirming behavioral control is typically sufficient. Mares receiving altrenogest for pregnancy maintenance require regular reproductive examinations to assess pregnancy viability and determine appropriate treatment duration. Long-term treatment may warrant periodic assessment including physical examination and potentially blood work to evaluate overall health. Uterine examination may be indicated for mares showing signs of fluid accumulation or those on extended treatment programs. Keeping treatment records including start dates, doses, and observed responses facilitates ongoing management and veterinary communication.

Special population considerations include particular attention to mares with underlying health conditions and those in various reproductive states. Mares with a history of reproductive abnormalities should have thorough evaluation before beginning progestin therapy. Young mares that have not yet established regular cyclicity may respond differently than mature mares. Geriatric mares, particularly those with PPID or other metabolic conditions, warrant individualized assessment. Lactating mares generally should not receive altrenogest unless specifically indicated under veterinary guidance, as effects on lactation are not well characterized. Treatment decisions for special populations should involve thorough veterinary evaluation.

Competition and performance horse precautions are critical given altrenogest's prohibited status under most competition rules. The extended detection times mean that competition mares cannot simply discontinue treatment before an event and expect to test clean. Planning for competition seasons must account for detection time guidelines, which vary by regulatory body and testing methodology. Mares showing estrus-related behavioral issues affecting competition may need alternative management strategies if altrenogest is not a viable option within competition timelines. Maintaining detailed treatment records protects owners in case of questions about competition compliance.

Administration precautions focus heavily on human safety due to altrenogest's significant risk of percutaneous absorption and potential effects on human reproduction. Protective gloves must be worn during administration and when handling treated horses, particularly around the head and mouth area where medication residue may be present. Pregnant women or women who may become pregnant must not handle altrenogest or treated horses. Skin contact requires immediate washing with soap and water. Safety data sheets should be available and reviewed by anyone handling the product. Disposal of unused medication, empty containers, and used gloves should follow hazardous material guidelines. Establishing facility protocols for safe handling protects everyone involved in altrenogest administration and horse care.

Long-term use considerations include monitoring for subtle effects that may develop with extended treatment. Prolonged progestin exposure may affect uterine health, and periodic reproductive examination is advisable for mares on long-term treatment. Effects on bone metabolism have been reported with synthetic progestins, warranting awareness in mares receiving extended treatment. The reversibility of altrenogest effects generally allows return to normal cyclicity after discontinuation, but prolonged treatment may require longer recovery periods. Regular reassessment of the need for continued treatment helps ensure mares receive progestin therapy only as long as genuinely indicated. Documentation of treatment duration and any observed effects informs future reproductive management decisions.

Storage requirements for altrenogest products follow manufacturer specifications, typically involving storage at controlled room temperature between 15-30°C (59-86°F) protected from light and moisture. The oil-based formulation should be stored in original containers with caps securely tightened to prevent evaporation of volatile components and contamination. Freezing should be avoided as this may affect product consistency and dosing accuracy. Storing altrenogest in a secure location away from other feed and supplements prevents accidental contamination and restricts access to authorized handlers only. Barn and tack room storage may be acceptable if temperature extremes are avoided, though climate-controlled storage is preferable for maintaining product integrity throughout the labeled shelf life.

Handling and safety precautions for altrenogest are more stringent than for most equine medications due to significant human health risks from percutaneous absorption. The medication carries FDA black box warnings regarding risks to pregnant women and women of childbearing potential. All handlers must wear protective gloves during administration, and skin contact requires immediate washing with soap and water. Protective gloves should also be worn when handling the mouths or faces of recently treated horses, where medication residue may be present. Eating, drinking, or smoking during or immediately after handling altrenogest is contraindicated. Contaminated gloves and materials should be disposed of as hazardous waste. Anyone experiencing accidental exposure should seek medical advice. Facilities using altrenogest should establish written safety protocols and ensure all personnel are properly trained.

Expiration and disposal guidelines must be carefully followed for altrenogest due to both efficacy and safety concerns. Products should be used before the manufacturer's expiration date, with expired medication disposed of according to hazardous material guidelines rather than regular waste streams. Many states have specific requirements for disposal of hormonal products, and veterinary clinics or pharmacies may accept unused medication for proper disposal. Never pour altrenogest down drains or dispose with regular garbage. Empty containers should be triple-rinsed and disposed of as hazardous waste, or handled according to local regulations for pharmaceutical containers. Maintaining expiration date awareness and proper inventory management prevents accumulation of expired product requiring disposal.

Draft breeds and their crosses receiving altrenogest require dosing adjustment based on their larger body mass, with doses calculated according to actual body weight. A 900 kg draft mare requires nearly double the dose of an average light horse, making accurate weight determination particularly important. Draft mares may be used in competitive driving, pulling, or breed shows where drug rules apply, necessitating awareness of withdrawal requirements. The generally calmer temperament often associated with draft breeds may mean that behavioral indications for altrenogest are less common, though individual variation exists. Draft breed characteristics do not affect altrenogest metabolism or efficacy, and standard protocols apply with appropriate dose scaling.

Light horse breeds and warmbloods represent the most common recipients of altrenogest therapy, particularly for performance applications in disciplines including dressage, show jumping, eventing, and hunters. These mares frequently receive altrenogest for estrus-related behavioral management during competition seasons. Standard dosing protocols are well-established for typical light horse weights. Warmbloods at the larger end of the weight spectrum require dose adjustments similar to draft crosses. Breed-specific considerations relate primarily to the competitive disciplines involved and associated drug testing requirements rather than differences in drug response. Thoroughbreds in racing jurisdictions face particularly stringent drug testing with potential career implications for positive tests.

Ponies and miniature horses require careful dose calculation based on their smaller body weights, as the standard measuring devices included with altrenogest products may make small-volume dosing less precise. A 300 kg pony requires approximately 6 mL daily, while miniature horses may require only 2-3 mL. Using more precise measuring devices may improve dosing accuracy for small equines. Show ponies in competitive programs face similar drug testing considerations as their larger counterparts. The economic considerations of altrenogest therapy may be proportionally different for smaller equines where drug costs per animal are lower but the relative investment in individual animals may still be significant.

Breed-specific sensitivities to altrenogest have not been extensively documented, and the medication is used across all horse breeds without known breed-specific contraindications. Arabians and related breeds used in endurance competition must comply with FEI drug rules, including altrenogest restrictions. Quarter Horses and related breeds in stock horse disciplines face AQHA and associated organization drug testing requirements. Breeds with known genetic conditions affecting metabolism do not have documented interactions with altrenogest, though mares with HYPP, PSSM, or other genetic conditions should have overall health status evaluated when any medication is considered. Individual mare factors including reproductive history and temperament typically influence treatment decisions more than breed characteristics.

Same class alternatives to altrenogest include other progestin compounds used in equine medicine, though altrenogest remains the most commonly used oral progestin for mares. Injectable progesterone in oil provides another option for progestin supplementation, particularly for pregnancy maintenance, though it requires daily injections and may cause injection site reactions. Compounded progesterone preparations may be available from veterinary compounding pharmacies, though quality and potency may be less consistent than commercial products. Hydroxyprogesterone caproate has been used in some reproductive protocols. For most indications, altrenogest's ease of oral administration and established efficacy make it the preferred choice among available progestins.

Different class options for managing conditions commonly treated with altrenogest depend on the specific indication. For estrus suppression in performance mares, intrauterine devices (marbles or similar) have been used to maintain corpus luteum function, though efficacy is variable. Oxytocin injections during diestrus may help extend luteal function in some mares. GnRH vaccines designed to suppress reproductive hormone production offer longer-acting alternatives, though availability may be limited and effects are less readily reversible. For behavioral management not specifically related to estrus, other approaches including training modification, environmental management, or medications targeting behavior through non-hormonal mechanisms may be appropriate.

Complementary therapies and guidance for mares receiving altrenogest often involve comprehensive reproductive management. Mares treated for estrus suppression benefit from regular exercise and training programs taking advantage of improved behavioral consistency. Those receiving treatment for pregnancy maintenance require appropriate gestational monitoring and management. Nutritional support appropriate to the mare's reproductive status and workload complements pharmaceutical management. Veterinary guidance is essential for determining appropriate treatment protocols, monitoring response, and making decisions about treatment duration and discontinuation. Never substitute or modify altrenogest treatment without veterinary consultation, as inappropriate use can have significant reproductive consequences.